

RESEARCH

Open Access

# *Haemophilus influenzae* porine ompP2 gene transfer mediated by graphene oxide nanoparticles with effects on transformation process and virulence bacterial capacity

Julia Nogueira Varela<sup>1</sup>, Maria Cecília Krähenbühl Amstalden<sup>1</sup>, Rafaella Fabiana Carneiro Pereira<sup>1</sup>, Luciana Maria de Hollanda<sup>1</sup>, Helder José Ceragioli<sup>2</sup>, Vitor Baranauskas<sup>2</sup> and Marcelo Lancellotti<sup>1\*</sup>

## Abstract

**Background:** *H. influenzae* is a natural competent bacterium that can uptake DNA from the environment and recombine into bacterial genome. The outbreaks of Brazilian purpuric fever, heavily polluted areas of a different *H. influenzae* biogroup - *aegyptius* - as well as gene transference between *Neisseria meningitidis* make the transformation process an important evolutionary factor. This work studied the horizontal transference of the *ompP2* gene from a multiresistant strain of *H. influenzae* 07 (NTHi), under the influence of graphene oxide nanoparticles in order to mimic an atmosphere rich in suspended particles and this way verify if the CFU transformants number was increased.

**Material and methods:** In this article the gene *ompP2* was transformed into different strains of *H. influenzae* mediated or not by graphene oxide nanoparticles in suspension, followed by the adhesion tests in Hec-1B (human endometrium adenocarcinoma) and A549 (pulmonary epithelial carcinoma) cells lines. The transformation frequency and the adhesion capacity were determined in all the mutants to which the *ompP2* gene was transferred and compared to their wild type strains.

**Results:** The nanoparticles increased the transformation ratio of one particular strain isolated from a pneumonia case. The adhesion patterns to A549 and Hec1b cell lines of these mutated bacteria has their capacity increased when compared to the wild type.

**Conclusions:** Graphene oxide nanoparticles aid the transformation process, helping to increase the number of CFUs, and the mutants generated with the *ompP2* gene from a *H. influenzae* resistant strain not only present a chloramphenicol resistance but also have an increased adherence patterns in A549 and Hec1B cell lines.

**Keywords:** *Haemophilus influenzae*, Graphene oxide, Bacterial transformation, Outer membrane protein, Virulence, Porin

## Background

*Haemophilus influenzae* is a gram-negative pleomorphic coccobacillus that usually colonizes the upper respiratory tract in humans. This specie can be classified by two methods: biotypes and serotypes. The division into biotypes is based on the presence and production of enzymes such as ornithine decarboxylase, urease and those that act

on fermentation of D-xylose and on the production of indol. With this classification, *Haemophilus influenzae* can be divided into 9 biotypes: I to VIII and *aegyptius* [1,2]. *H. influenzae* can also be classified based on the production of a polysaccharide capsule composed by a 3- $\beta$ -ribose-(1-1)-ribitol-phosphate polymer (RPR), whose antigenic structure divides the capsulated strains into 6 immunologic known serotypes: a – f [3] and non-typed strains, which do not produce capsule [4]. Other methods such as membrane protein analysis, lipopolysaccharide profile and isoenzymes electrophoresis can be used for the

\* Correspondence: mlancell@unicamp.br

<sup>1</sup>LABIOTEC - Biotechnology Laboratory, Department of Biochemistry, Institute of Biology CP6109, University of Campinas - UNICAMP 13083-970, Campinas, São Paulo, Brazil

Full list of author information is available at the end of the article

purpose of studying and understanding the epidemiology of *H. influenzae* [5].


*H. influenzae* type b is the most invasive of all serotypes and known as the main causer of meningitis, as well as the most relevant pathogen of the upper respiratory tract in children and in adults [6-9]. *H. influenzae* is responsible for 30 to 50% of all bacterial meningitis over the world and the second most common agent of pneumonia in children [10]. The non-typed forms of *H. influenzae* (NTHi) are generally associated to moderate diseases of the upper respiratory tract in children and pneumonia in adults with Chronic Obstructive Pulmonary Disease (COPD) or Cystic Fibrosis [11]. The polysaccharidic capsule is considered the main antigen of this microorganism [3]. Another important pathogen factor is the lipopolysaccharides (LPS) associated with outer membrane proteins (OMP), which causes high fever and coagulation disorders [12].

*H. influenzae* resistance to antibiotics increased significantly over the last 20 years. This resistance is worse to beta-lactamic drugs, due to their production of beta-lactamase [13]. Since the first reports of *H. influenzae* resistant strains to ampicillin in 1974 in the USA, the main proposed mechanism was the production of beta-lactamases TEM-1 and ROB-1 by plasmids. The prevalence of beta-lactamase producing strains increased 15, 2% from 1983 to 1984 and 31, 3% from 1997 to 1998. *H.*

*influenzae* is not only resistant to ampicillin; they also present non-susceptibility to cephalosporin, trimethoprim, cephalosporin, tetracycline and sulfonamides [14-17].

One of the main reasons for the emergence of multiresistant strains over the last years is the horizontal gene transfer. *H. influenzae* is considered to be natural competent, i.e., a bacterium capable of taking up exogenous DNA and incorporating it into its own genetic material by transformation [18,19]. These new genes incorporated onto the genetic code may provide mechanisms to avoid or inhibit the action of antimicrobial drugs. Even small amino acid changes in proteins can enhance the resistance of bacteria to drugs. One example is the Outer Membrane Proteins (OMP) also known as porines, which in *H. influenzae* are classified from P1 to P6, in order of their decreasing molecular weight (Figure 1) [20]. Small changes on the amino acid sequence of one of these proteins were related to an increase of antibiotics resistance in *Haemophilus influenzae* strains isolated from cystic fibrosis patients [21]. Porines isolated from resistant strains present a lower electric conductivity than wild-type porines. This would explain the non-susceptibility to beta-lactamic antibiotics and other drugs with low molecular weight [22].

The use of organic and inorganic nanomaterials is nowadays a new promising tool to biomedical researches, as for example in cancer treatment and diagnostics, drug delivery systems and bacterial processes [23]. Researches



**Figure 1** Field emission electron microscopy show in different size and magnification of graphene oxide (in A: panoramic view, B: micrometric scale and C: nanometric scale).

have shown that transformation frequencies and transformation process can be influenced by nanoparticles, especially mesoporous silica and carbon nanotubes [24-26]. Graphene oxide nanoparticles (GON), a layered structure of oxidized graphene sheets with epoxy- and hydroxyl groups at their edges, is a new material that attracts attention due to their distinct electronic, thermal and mechanical properties [27,28]. However, their potential role on bacterial transformation is still unknown. As graphene is composed by carbon atoms, it shows similar chemical characteristics to nanoparticles present in the atmosphere of highly polluted regions, provoking respiratory disorders when these particles are inhaled.

This work aimed to see the effect of graphene oxide nanoparticles on the transformation frequency of *H. influenzae*; especially on the horizontal transfer of *ompP2* amplicon obtained from NTHi serotype 07, resistant to chloramphenicol and tetracycline; as well as to verify the adhesion of mutant and wild-type strains on cells A549 and Hec-1-B in the presence of antibiotics.

## Methods

### Bacterial strains

All strains used in this work are listed in Table 1. *H. influenzae* strains were grown in chocolate agar or BHI agar (Difco) supplemented with NAD (Sigma, Saint Louis, MO, USA) 0,2 mg/ml and hemin (Sigma, Saint Louis, MO, USA) 2 mg/ml at 37°C with 5% CO<sub>2</sub> for 18–24 hours.

### Cell cultures

Cell lines A549 (pulmonary epithelial carcinoma) and Hec-1-B (human endometrium adenocarcinoma) were obtained at the Institute Adolfo Lutz, Brazil. They were cultivated at RPMI medium 1640 (Cultilab, Campinas, Brazil) with 10-20% Bovine Fetal Serum (BFS), depending the cellular lineage, and maintained at 37°C with 5% CO<sub>2</sub>. After the

semiconfluent cell layer formation, the cells were trypsinized and transferred to a 24-well polystyrene plate. Each well received 1 ml of cell culture and the cell concentration after its trypsinization was 1.106 cells/ml. Cells were incubated under same conditions as previously described.

### Graphene oxide nanoparticles synthesis

Graphene oxide nanoparticles were prepared after a catalytic conversion using a copper substratum. 1 ml of a polyaniline diluted in dimethylformamide was added on the substratum and dried in room temperature for two hours. On the substratum with polyaniline was put 0,2 ml of a solution of nickel nitrate diluted in acetone. Copper substratum was immersed into a chemical vapor deposition reactor assisted by a hot filament. The reactor contained a carbon source formed by camphor, acetone and citric acid. Raman spectrometry and Field Emission Scanning Electron Microscopy can be seen in Figure 2.

### ompP2 gene amplification

Genomic DNA from *H. influenzae* strain NTHi 07 was extracted using the protocol described by Sambrook et al. [29]. The sequence of the gene *ompP2* was obtained at Genbank GI:2981106 (<http://www.ncbi.nlm.nih.gov/nucleotide>). Primers used to gene amplification are listed in Table 2.


### Transformation process

Grown bacteria were transferred to BHI broth supplemented with NAD 2 µg/ml and hemin 10 µg/ml at a final concentration of D<sub>600</sub> 1,0. Transformation process was made using 100 µl of bacterial solution incubated with 5 µl of *ompP2* amplicon at a concentration of 1 µg/ml, followed by the addition of 15 µl of graphene oxide nanoparticles at a concentration of 20 µg/ml for 30 minutes. Afterwards, 1 ml of supplemented BHI broth was added

**Table 1 Bacterial strains used in this work**

Strains	Characteristics	Origin
Rd	<i>Haemophilus influenzae</i> standard strain completely sequenced, from serotype d	INCQS – FIOCRUZ
Hib-βlac	<i>Haemophilus influenzae</i> serotype b ATCC	INCQS – FIOCRUZ
Hi07	<i>Haemophilus influenzae</i> NTHi - CmR, TcR, ApR	LABIOTEC
Hi38	<i>Haemophilus influenzae</i> serotype a isolated from a pneumonia case	LABIOTEC
Hi13	<i>Haemophilus influenzae</i> NTHi hmw+	LABIOTEC
Hi45	<i>Haemophilus influenzae</i> serotype b isolated from an hemoculture	LABIOTEC
Hi46	<i>Haemophilus influenzae</i> serotype b isolated from a hemoculture	LABIOTEC
Hi47	<i>Haemophilus influenzae</i> NTHi isolated from a hemoculture	LABIOTEC
Hic	<i>Haemophilus influenzae</i> serotype c ATCC 9007 NCTC 8469.	IAL – SP
Hie	<i>Haemophilus influenzae</i> serotype e NCTC 10479.	IAL – SP
Hif	<i>Haemophilus influenzae</i> serotype f NCTC 7918.	IAL – SP

IAL – Adolfo Lutz Institute SP, INCQS – FIOCRUZ – National Institute of Quality Control - Oswaldo Cruz Foundation.  
 LABIOTEC – Biotechnology Laboratory – IB – UNICAMP.



**Figure 2** Transformation frequency with and without the presence of Graphene Oxide Nanoparticles, with  $p < 0,001$  (\*\*\*)

and the transformation was incubated at 37°C with 5% CO<sub>2</sub> for 3 hours. An aliquot of 100 µl was then transferred to BHI agar plate containing 2 µg/ml of chloramphenicol and incubated for 18 hours under the same described conditions. Negative control was made without the use of nanoparticles. Transformed CFU were count and statistical analysis was made by comparing the number of transformants obtained with and without the use of nanoparticles. To verify the successful gene acquisition, a PCR was made under the same conditions as previously described.

#### Cytotoxicity assay

Cytotoxicity tests were made to analyze whether the antibiotic present in bacterial medium would interfere on cellular growth. After 24 hours of incubation, the medium was removed, the wells were washed 3 × with 0.1 mL of PBS Buffer (137 mM NaCl, 10 mM phosphate, KCl 2.7 mM, and a pH of 7.4). 0.2 mL of RPMI1640 was added in each well. An initial concentration of chloramphenicol of 4 µg/ml was added into the first wells and diluted into half concentration in each well. After incubation for 3 h at 37°C, the medium with dye was removed and carefully 0.2 mL of ethanol was added to solubilize the blue formazan (yielded from MTT reduction by viable cells). The plates were shaken for 10 minutes and the absorbance for each well was read in a spectrophotometer ELx800 Absorbance Microplate Reader (BioTek, USA) at  $\lambda = 570$  nm. The values were expressed as percentages of MTT reduction compared to the control, where cells were not exposed to test agents [30].

#### Neutral red (NR) uptake assay

The Neutral Red uptake assay was performed as described [31]. After incubation, the medium containing the dye was removed and the wells were rapidly washed with 0.2 ml of calcium-formaldehyde solution (10 ml of 40% formaldehyde, 10 ml of CaCl<sub>2</sub>; 10 ml deionized water). The solution was discarded and 0.2 mL of ethanol-acetic acid was added (1 ml of glacial acetic acid, 100 ml of ethanol 50%). The plate was kept for 15 minutes at room temperature and the absorbance for each well was read in a spectrophotometer ELx800 Absorbance Microplate Reader (BioTek, USA) at  $\lambda = 540$  nm [32]. The values were expressed as percentages of NR uptake compared to the control, in which the cells were not exposed to test agents.

#### Adhesion assay

Adhesion assay on cells was performed based on the description of Scaletsky et al. [33]. 50 µl of bacterial suspension with a concentration of 1.106 CFU/ml was added into each well containing 1 ml of RPMI 1640 with 10% BFS and 2 µg/mL of chloramphenicol. After an incubation period of 3 hours at 37°C with 5% CO<sub>2</sub>, cellular medium was removed and each well was washed five times with RPMI 1640, to remove bacteria that did not adhere to the cells. 1 ml of RPMI was added to each

**Table 2** Primers used

Primer	Nucleotids sequence 5'- 3'	Description
PorHi Fw	ATTAATCGTTGGTGCATTTCG	<i>porHi forward</i>
Por Hi Rev	GAAGTAAACGCGTAAACCTACAC	<i>porHi reverse</i>

well and its bottom was scraped with a micropipette tip to release adhered bacteria. An aliquot of 50  $\mu$ l was taken and plated into chocolate agar medium with chloramphenicol for the mutant strain and without the antibiotic for wild-type strains. The plates were incubated for 18 hours at 37°C with 5% CO<sub>2</sub> and CFU were counted.

### Statistical analysis

Statistical analysis was performed using GraphPad InStat program: transformation efficiency was analyzed by Bonferroni test with the number of CFU transformants with and without the presence of graphene oxide nanoparticles. Considered values were  $p < 0.05$ . The adhesion assay was analyzed by Tukey's test with a comparison of a control sample. All experiments were made in triplicate.

## Results and discussion

### Transformation process and resulting frequencies

The graphic of transformation frequencies with and without the use of nanoparticles for each *H. influenzae* strain is shown in Figure 3. As we can see, the transformation frequencies vary among the strains. *Hi38*, *Hi45*, *HiF*, *Hi $\beta$ lac* and *HiRd* presented an increased transformation frequency with the presence of GON, whereas for the strains *Hi13* and *Hi47* these values were decreased. However, the only strain that presented an extremely significant value of  $p < 0.001$  is *H. influenzae* 38, as shown in Table 3.

The verification of *ompP2* incorporation into the genomic DNA of the receptor strains was made by PCR analysis (data not shown). Studies of how nanoparticles effect transformation processes have already been made, proving to have an increase on its frequency. One hypothetical mechanism for this phenomenon could be explained by a complexation of the nanomaterial with DNA, avoiding its degradation by DNase enzymes. The uptake of DNA and its incorporation into bacterial genetic material could be facilitated by these nanoparticles [24,25].


GON are found in high concentration in polluted atmospheres, especially in arid regions. This way, the study of their influence on *H. influenzae* transformation mimics a natural environment of carbon nanoparticles in the atmosphere, helping the transformation process in bacteria that asymptotically colonizes the upper respiratory tract in humans. In certain regions were primitive agriculture is practiced, performed by sugar cane burning, the resulting emission of micro and nanoparticles generate a major series of respiratory complications and infections [34]. This way, the only strain which presented a statistically significant increase of transformation frequency is *H. influenzae* 38. Interestingly, this strain distinguishes itself from the other studied strains by being clinically isolated from a pneumonia sample (Table 1); because of that, this bacterium can be more adapted to a carbon nanoparticle-concentrated atmosphere and therefore may use them in its own favor than strains isolated from blood cultures. As graphene oxide nanoparticles present a similar structure and physical-chemical characteristics than multi-walled carbon nanotubes and mesoporous silica nanoparticles, it is believed that these nanostructures share the same action mechanisms in transformation processes. Therefore, the same hypothesis previously presented can be applied to explain the major increase of transformation frequency of *H. influenzae* strain 38 with the presence of graphene oxide nanoparticles.

### Cytotoxicity

Graphics of cellular viability under the effects of chloramphenicol results are shown in Figure 4. The highest concentration (4  $\mu$ g/ml) led to a decrease of 20% for Hec-1-b and A549. For the concentration of 2  $\mu$ g/ml used in the adhesion assay, the cell viability resulted in 83%, thus chloramphenicol is not considered toxic under these conditions.

### Adhesion assay

The graphics of cellular adhesion for wild-type and mutant strains in A549 and Hec1B cells with and without



**Figure 3** Cytotoxicity in A549 and Hec1B cell lines.

**Table 3 Transformation tax value per colony forming unit and standard deviation**


Strains	CFU	STD
Hi13	24.667	3.786
Hi13 gon	16	5
Hi38	31.333	7.234
Hi38 gon	106	14.177
Hi45	23	7.937
Hi45 gon	33.33	3.215
Hi47	14.33	1.528
Hi47 gon	8.667	3.215
HiF	75.667	16.258
HiF gon	80	12.49
Hiβlac	62	18.52
Hiβlac gon	73.33	22.301
HiRd	10.33	4.041
HiRd gon	40	26.889


the presence of chloramphenicol can be seen in Figure 5. Wild-type strains of *H. influenzae* did not present any statistical relevant values for adhesion in A549 cells with or without the presence of antibiotics, while mutant strains C and βlac show an increase of adhesion when

chloramphenicol was added, resulting into a significant  $\rho$  value of  $p < 0.05$ . By comparing wild-type and mutant strains, the adhesion of the first ones with and without chloramphenicol in A549 cells had an increase of  $p < 0.05$  and  $p < 0.001$ , respectively.

As for the adhesion results in Hec1B cells, mutant strain Hi13M showed an increase of its adhesion in the presence of antibiotics when compared to the adhesion with its absence, with  $p < 0.05$ . In an environment without chloramphenicol, Hi46M also had an increase with a significant value of  $p < 0.05$  compared to its wild-type strain. The comparison between wild-type and mutant strains with antibiotics presence revealed a clear increase of adhesion by the mutant strains. *H. influenzae* 13, 47, C and βlac mutant and wild-type strains presented an extremely significant  $p$  value of  $< 0.001$ , while 46 strain had a very significant value of  $p < 0.01$ .

The adhesion assay to see the influence of mutation of *ompP2* gene was proposed due to the importance of bacterial adherence at the mucosal surface on host organisms as a virulence factor [33]. The pulmonary adenocarcinoma cell lineage A549 was chosen due to *H. influenzae* predilection of respiratory tract [31], while Hec1B cells of endometrial adenocarcinoma were used with the purpose of mimetizing an endothelium [35]. As cytotoxicity results presented a cellular viability of over 80% at the highest





concentration used of chloramphenicol (2 µg/ml), it would not affect the cellular growth of neither A549 nor Hec1B lineages. *ompP2* provides *H. influenzae* with resistance to chloramphenicol, thus the presence of this antibiotic in the medium increases the gene expression in mutant strains, at the same time it inhibits the bacterial growth in wild-type strains. Therefore, it was already expected that mutant strains presented a higher adhesion in cell cultures than wild-type ones. Nonetheless, the adhesion taxes without the presence of antibiotics also presented increased results for the majority of mutant strains, with a significant value of  $p < 0.05$  for Hi47M, HiCM and HiβlacM in A549 cells, while all mutant variants showed highly significant  $p$  values of  $p < 0.01$  and  $p < 0.001$  in Hec1B cells.

Bacterial strains presented different adhesion taxes on A549 and Hec1B cells. While all mutant strains showed a major adhesion with and without antibiotics in Hec1B cells, with a significant  $p$  value when compared to their wild-type, this behavior could not be seen in A549 cells. One possible explanation is the fact that *H. influenzae* is a commensal bacterium of the upper respiratory tract and therefore wild-type strains present a natural capability of adhesion on these cells. On the other hand, these bacteria only have contact with endothelial cells in meningitis cases. As this microenvironment does not permit a

direct transition from one host to another, the adhesion on Hec1B does not present any natural evolutionary potential for *H. influenzae* [36,37]. The acquisition of *ompP2* gene obtained from Hi07 strain not only provided a resistance to chloramphenicol, but also increased the adhesion taxes especially in Hec1B cells.

*H. influenzae* type b P2 porine (341 amino acids, 37.782 Da) allows the diffusion of small molecules with a molecular weight of until 14000 Da to the periplasmic space [38]. This is probably the antibiotics way of access into the bacterial cell. Small changes on the amino acid configuration provide different molecule captures by closing the canal, therefore modifying the porine function [39]. The basic amino acid changes in the porine overture loop domains 1 and 3 could difficult the penetration of chloramphenicol to the inner side of *H. influenzae*, resulting into a resistance to this antibiotic and also into a better adhesion to cell cultures.

The adhesion of mutant *H. influenzae* strains on human cells surface is directly linked to the influence of graphene oxide nanoparticles on bacterial transformation, once the resulting mutants presented a higher adhesion to cell lines compared to wild type strains. Some studies have already related atmospheric pollution to cases of bacterial meningitis [40,41]. Therefore, this study corroborates to the

hypothesis that links greater transformation frequency of naturally competent bacteria to the influence of nanoparticles and its consequences to the health of people exposed to them, especially in polluted and arid regions.

## Conclusions

Graphene oxide nanoparticles aid the transformation process, helping to increase the number of CFUs, and the mutants generated with the *ompP2* gene from a *H. influenzae* resistant strain not only present an chloramphenicol resistance but also have an increased adherence patterns in A549 and Hec1B cell lines. Also, the increase of transformation frequency have some relationships with the adhesion, or the virulence of this bacterium. Then a gene linked to antibiotic resistance acquisition showed a great capacity of not only antibiotic transference characteristics between *H. influenzae* strains as the transference of the virulence factors present in different strains in human upper respiratory tract.

## Competing interests

All the authors declare that they have no competing interests in this work.

## Authors' contributions

JNV carried out the Molecular Biology design and plasmids; MCKA carried out the results analysis and revised the manuscript; RFCP carried out the cellular assays tests; LMH carried out the molecular genetics studies; HJC carried out the graphene synthesis and FESEM, HRTEM and Raman tests; VB participated in the drafting of the manuscript and gave technical support in Nanoengineering; ML carried out the molecular genetics studies and also the draft of the manuscript. All the authors read and approved the final manuscript.

## Acknowledgements

Thanks for FAPESP (Grants 2011/14079-2, 2011/21685-6 and 2012/15046-3) and CAPES (fellowship grants for Varela JN) for the financial support for the LABIOTEC.

## Author details

<sup>1</sup>LABIOTEC - Biotechnology Laboratory, Department of Biochemistry, Institute of Biology CP6109, University of Campinas - UNICAMP 13083-970, Campinas, São Paulo, Brazil. <sup>2</sup>NanoEng - NanoEngineering and Diamond Laboratory, School of Electrical and Computer Engineering, Department of Semiconductors, Instruments and Photonics, University of Campinas, UNICAMP, Av. Albert Einstein N.400, CEP 13 083-852 Campinas, São Paulo, Brazil.

Received: 15 January 2014 Accepted: 4 April 2014

Published: 16 April 2014

## References

1. Wolf J, Daley AJ: Microbiological aspects of bacterial lower respiratory tract illness in children: typical pathogens. *Paediatr Respir Rev* 2007, **8**:204–210. quiz 210–201.
2. Holt JG, Krieg NR, Sneath PHA, Staley JT, Williams ST: **Facultatively Anaerobic Gram-negative Rods**. In *Bergey's Manual of Determinative Bacteriology*. 9th edition. Baltimore: Williams & Wilkins; 1994:175–290.
3. Kroll JS, Langford PR, Loynds BM: Copper-zinc superoxide dismutase of *Haemophilus influenzae* and *H. parainfluenzae*. *J Bacteriol* 1991, **173**:7449–7457.
4. Gilsdorf JR, Marrs CF, Foxman B: *Haemophilus influenzae*: genetic variability and natural selection to identify virulence factors. *Infect Immun* 2004, **72**:2457–2461.
5. Rahman M, Hossain S, Baqui AH, Shoma S, Rashid H, Nahar N, Zaman MK, Khatun F: *Haemophilus influenzae* type-b and non-b-type invasive diseases in urban children (<5 years) of Bangladesh: implications for therapy and vaccination. *J Infect* 2008, **56**:191–196.
6. Bae S, Lee J, Kim E, Lee S, Yu J, Kang Y: Antimicrobial resistance in *Haemophilus influenzae* respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. *Antimicrob Agents Chemother* 2010, **54**:65–71.
7. Turk DC: The pathogenicity of *Haemophilus influenzae*. *J Med Microbiol* 1984, **18**:1–16.
8. Booy R, Heath PT, Slack MP, Begg N, Moxon ER: Vaccine failures after primary immunisation with *Haemophilus influenzae* type-b conjugate vaccine without booster. *Lancet* 1997, **349**:1197–1202.
9. Wang SR, Tseng MH, Lin WJ, Teng CS, Wang CC: Fatal non-typeable *Haemophilus influenzae* sepsis complicated with acute respiratory distress syndrome: case report and literature review. *Scand J Infect Dis* 2005, **37**:921–925.
10. Barenkamp SJ, Munson RS Jr, Granoff DM: Subtyping isolates of *Haemophilus influenzae* type b by outer-membrane protein profiles. *J Infect Dis* 1981, **143**:668–676.
11. Foxwell AR, Kyd JM, Cripps AW: Nontypeable *Haemophilus influenzae*: pathogenesis and prevention. *Microbiol Mol Biol Rev* 1998, **62**:294–308.
12. Murphy TF, Bartos LC: Purification and analysis with monoclonal antibodies of P2, the major outer membrane protein of nontypable *Haemophilus influenzae*. *Infect Immun* 1988, **56**:1084–1089.
13. Murphy TF, Bartos LC: Human bactericidal antibody response to outer membrane protein P2 of nontypeable *Haemophilus influenzae*. *Infect Immun* 1988, **56**:2673–2679.
14. Arbing MA, Hanrahan JW, Coulton JW: Altered channel properties of porins from *Haemophilus influenzae*: isolates from cystic fibrosis patients. *J Membr Biol* 2002, **189**:131–141.
15. Regelink AG, Dahan D, Moller LV, Coulton JW, Eijk P, Van Ulsen P, Dankert J, Van Alphen L: Variation in the composition and pore function of major outer membrane pore protein P2 of *Haemophilus influenzae* from cystic fibrosis patients. *Antimicrob Agents Chemother* 1999, **43**:226–232.
16. Gazagne L, Delmas C, Bingen E, Dabernat H: Molecular epidemiology of ampicillin-resistant non-beta-lactamase-producing *Haemophilus influenzae*. *J Clin Microbiol* 1998, **36**:3629–3635.
17. Yamanaka N, Hotomi M, Billal DS: Clinical bacteriology and immunology in acute otitis media in children. *J Infect Chemother* 2008, **14**:180–187.
18. Dimopoulou ID, Kraak WA, Anderson EC, Nichols WW, Slack MP, Crook DW: Molecular epidemiology of unrelated clusters of multiresistant strains of *Haemophilus influenzae*. *J Infect Dis* 1992, **165**:1069–1075.
19. Dimopoulou ID, Jordens JZ, Legakis NJ, Crook DW: A molecular analysis of Greek and UK *Haemophilus influenzae* conjugative resistance plasmids. *J Antimicrob Chemother* 1997, **39**:303–307.
20. Leaves NI, Dimopoulou I, Hayes I, Kerridge S, Falla T, Secka O, Adegbola RA, Slack MP, Peto TE, Crook DW: Epidemiological studies of large resistance plasmids in *Haemophilus*. *J Antimicrob Chemother* 2000, **45**:599–604.
21. Cerquetti M, Ciofi degli Atti ML, Cardines R, Giufre M, Romano A, Mastrantonio P: *Haemophilus influenzae* serotype e meningitis in an infant. *Clin Infect Dis* 2004, **38**:1041.
22. Burns JL, Mendelman PM, Levy J, Stull TL, Smith AL: A permeability barrier as a mechanism of chloramphenicol resistance in *Haemophilus influenzae*. *Antimicrob Agents Chemother* 1985, **27**:46–54.
23. Takahata S, Ida T, Senju N, Sanbongi Y, Miyata A, Maebashi K, Hoshiko S: Horizontal gene transfer of *ftsI*, encoding penicillin-binding protein 3, in *Haemophilus influenzae*. *Antimicrob Agents Chemother* 2007, **51**:1589–1595.
24. Maughan H, Redfield RJ: Tracing the evolution of competence in *Haemophilus influenzae*. *PLoS One* 2009, **4**:e5854.
25. Chen I, Dubnau D: DNA uptake during bacterial transformation. *Nat Rev Microbiol* 2004, **2**:241–249.
26. Maughan H, Redfield RJ: Extensive variation in natural competence in *Haemophilus influenzae*. *Evolution* 2009, **63**:1852–1866.
27. Zhao QQB A, CHOWDHRY U: Nanotechnology in the Chemical Industry – Opportunities and Challenges. *J nanoparticles Res* 2003, **5**:567–572.
28. Rojas-Chapana J, Trosczynska J, Firkowska I, Morszczek C, Giersig M: Multi-walled carbon nanotubes for plasmid delivery into *Escherichia coli* cells. *Lab Chip* 2005, **5**:536–539.
29. Mattos IB, Alves DA, Hollanda LM, Ceragioglu HJ, Baranauskas V, Lancellotti M: Effects of multi-walled carbon nanotubes (MWCNT)

- under *Neisseria meningitidis* transformation process. *J Nanobiotechnol* 2011, **9**:53.
30. Hollanda LM, Cury GC, Pereira RF, Ferreira GA, Sousa A, Sousa EM, Lancellotti M: **Effect of mesoporous silica under *Neisseria meningitidis* transformation process: environmental effects under meningococci transformation.** *J Nanobiotechnol* 2011, **9**:28.
  31. Borenfreund E, Borrero O: **In vitro cytotoxicity assays. Potential alternatives to the Draize ocular allergy test.** *Cell Biol Toxicol* 1984, **1**:55–65.
  32. Pereira RFC AD, Jacinto RK, Hollanda LM, Verinaud LMC, Machado CML, Lancellotti M: **Effects of *Neisseria meningitidis* Infection in Tumor Glioblastoma Cell Line NG97: Respiratory Pathogen Inducing Apoptosis.** *J Bacteriol Parasitol* 2011, **2**:4.
  33. Sambrook J, Fritsch EF, Maniatis T: *Molecular cloning: a laboratory manual*. CSH Laboratory Press; 1989.
  34. Konowalchuk J, Speirs JI, Stravic S: **Vero response to a cytotoxin of *Escherichia coli*.** *Infect Immun* 1977, **18**:775–779.
  35. Babich H, Puerner JA, Borenfreund E: **In vitro cytotoxicity of metals to bluegill (BF-2) cells.** *Arch Environ Contam Toxicol* 1986, **15**:31–37.
  36. Scaletsky IC, Silva ML, Trabulsi LR: **Distinctive patterns of adherence of enteropathogenic *Escherichia coli* to HeLa cells.** *Infect Immun* 1984, **45**:534–536.
  37. Kroll JS, Wilks KE, Farrant JL, Langford PR: **Natural genetic exchange between *Haemophilus* and *Neisseria*: intergeneric transfer of chromosomal genes between major human pathogens.** *Proc Natl Acad Sci U S A* 1998, **95**:12381–12385.
  38. Ribeiro H, Assunção JV: **Efeitos das queimadas na saúde humana.** *Estud Avançados* 2002, **16**:24.
  39. Foster KA, Oster CG, Mayer MM, Avery ML, Audus KL: **Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism.** *Exp Cell Res* 1998, **243**:359–366.
  40. Spence JM, Clark VL: **Role of ribosomal protein L12 in gonococcal invasion of Hec1B cells.** *Infect Immun* 2000, **68**:5002–5010.
  41. Benson SA, Occi JL, Sampson BA: **Mutations that alter the pore function of the OmpF porin of *Escherichia coli* K12.** *J Mol Biol* 1988, **203**:961–970.

doi:10.1186/1477-3155-12-14

**Cite this article as:** Varela et al.: *Haemophilus influenzae* porine ompP2 gene transfer mediated by graphene oxide nanoparticles with effects on transformation process and virulence bacterial capacity. *Journal of Nanobiotechnology* 2014 **12**:14.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

